ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). We're rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

news image

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More

Industrial Impact

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

news image

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

news image

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More

MedTech

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

news image

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More
news image

Medical

PFIZER AND BIONTECH BEGIN ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR FDA APPROVAL OF COVID-19 VACCINE IN THE U.S

Pfizer, BioNTech | May 10, 2021

Pfizer Inc. and BioNTech SE confirmed today the filing of a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in people aged 16 and above. Companies will send data to help the BLA to the FDA on a rolling basis in the coming weeks, along with a proposal for Priority Review. If the BLA has been completed and duly approved for review by the FDA, the FDA will set a target date for a determination under the Prescr...

Read More
news image

Industrial Impact

SHOUTI INTRODUCES BASECAMP BIO AS A WHOLLY OWNED SUBSIDIARY TO EXPAND PIPELINE AND PARTNERSHIPS

ShouTi Inc | February 18, 2022

ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships. Basecamp Bio integrates unique insights, skills, technological know-how and experience to navigate the complex challenges of membrane protein structure-based drug discovery. Its mission is to prosecut...

Read More
news image

GENE THERAPY OFFERS HOPE FOR UNTREATABLE CTE BRAIN DISORDER

Genetic Literacy Project | January 14, 2020

Researchers from Weill Cornell Medical College published a new study (“Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy”) in Human Gene Therapy that shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE....

Read More
news image

MedTech

WITH "PRODRUGS FOR CANCER TREATMENT" PATENT, GATC HEALTH ENTERS ONCOLOGY MEDICINE MARKET

GATC Health Corp | April 22, 2022

GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us